NIK inhibition was effective in all cell lines tested here: either as a monotherapy in RelB high DLBCL (Fig. 2B), to re-sensitize BCL2-sensitive DLBCL to ABT199 in the TME (Fig. 8D, E), or to re-sensitize BCLXL-sensitive DLBCL to BCLXL targeting BH3-mimetics in the TME (Fig. 8C). Here, BCL2L1 is linked to diffuse large B-cell lymphoma.